Vaxcyte, Inc.
HealthcareNASDAQ:PCVX · NASDAQ Global Select
+$0.29 today
Vol 1.02M · Avg 1.42M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$946.5M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-6.89, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $794.3M +66.6% | $476.6M +43.4% | $332.3M +96.1% | $169.5M +116.1% | $78.4M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $129.4M +39.3% | $92.9M +53.1% | $60.7M +52.5% | $39.8M +57.6% | $25.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $923.7M +62.2% | $569.5M +21.7% | $468.0M +101.5% | $232.3M +124.0% | $103.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $24.9M +56.9% | $15.8M +55.8% | $10.2M +7.6% | $9.5M +173.4% | $3.5M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$741.8M -65.5% | -$448.1M -14.3% | -$392.1M -83.2% | -$214.0M -121.5% | -$96.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$923.7M -62.2% | -$569.5M -21.7% | -$468.0M -101.5% | -$232.3M -124.0% | -$103.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $119.7M +8.8% | $110.0M +74.9% | $62.9M +652.8% | $8.4M +2329.1% | $344.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 -100.0% | $2.0K -71.4% | $7.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $157.0M +48.7% | $105.6M +60.6% | $65.8M +649.9% | $8.8M +144.1% | $3.6M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$766.6M -65.2% | -$463.9M -15.3% | -$402.3M -80.0% | -$223.5M -123.3% | -$100.1M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$766.6M -65.2% | -$463.9M -15.3% | -$402.3M -80.0% | -$223.5M -123.3% | -$100.1M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$6 -48.2% | -$4 +8.2% | -$4 -20.3% | -$3 -78.2% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$6 -48.2% | -$4 +8.2% | -$4 -20.3% | -$3 -78.2% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $136.1M +11.6% | $122.0M +25.6% | $97.2M +49.8% | $64.9M +25.0% | $51.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $136.1M +11.6% | $122.0M +25.6% | $97.2M +49.8% | $64.9M +25.0% | $51.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
$10.45B
Krystal Biotech, Inc.
NASDAQ:KRYS
$9.40B
TG Therapeutics, Inc.
NASDAQ:TGTX
$7.58B
Metsera, Inc.
MTSR
$7.43B
Alkermes plc
NASDAQ:ALKS
$7.43B
Arcellx, Inc.
ACLX
$6.73B
PTC Therapeutics, Inc.
NASDAQ:PTCT
$6.23B
CRISPR Therapeutics AG
NASDAQ:CRSP
$4.82B
Akero Therapeutics, Inc.
AKRO
$4.50B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.70B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does PCVX generate?
Vaxcyte, Inc. (PCVX) reported $0.00 of revenue in fiscal 2025.
Is PCVX profitable?
Vaxcyte, Inc. (PCVX) reported -$766,628,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.